• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 438907 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419241415 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419241415 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Antares Pharma Ranks the Highest in Terms of Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, CERS)

Published on Fri, 02/08/2013 - 11:18
By Peter Chu

Below are the three companies in the Health Care Supplies industry with the highest Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.

Antares Pharma (AMEX:AIS) is highest with an RPE of $1.1 million. Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company distributes its needle-free injector systems in various countries. Antares also conducts research and development with transdermal gel products and has several products in clinical evaluation with partners.

Potential upside of 61.6% exists for Antares Pharma, based on a current level of $3.30 and analysts' average consensus price target of $5.33. The stock should find initial support at its 50-day moving average (MA) of $3.04 and further support at its 200-day MA of $2.60.

Meridian Bioscience (NASDAQ:VIVO) is next with an RPE of $629,000.

Finishing up the top three is Cerus (NASDAQ:CERS), with an RPE of $464,000.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Earnings Look Back: Genesco Is Up 5.1% S...

When Genesco (NYSE:GCO) reported earnings two weeks ago on December 5th, 2014, analysts ...

Post Earnings Update: Vail Resorts Has C...

12 days ago, on December 8th, 2014, Vail Resorts (NYSE:MTN) reported its earnings. Ana ...

Cantel Medical Earnings Review: 10 Days ...

10 days ago, on December 10th, 2014, Cantel Medical (NYSE:CMN) reported its earnings. ...

ABM Industries Earnings Review: 12 Days ...

12 days ago, on December 8th, 2014, ABM Industries (NYSE:ABM) reported its earnings. A ...

Post Earnings Update: Gildan Activewear ...

Two weeks ago on December 4th, 2014 Gildan Activewear (NYSE:GIL) reported earnings and ...

Earnings Look Back: Christopher & Banks ...

When Christopher & Banks (NYSE:CBK) reported earnings two weeks ago on December 4th, 20 ...

Post Earnings Update: Methode Electronic...

9 days ago, on December 11th, 2014, Methode Electronics (NYSE:MEI) reported its earning ...

Phillips-Van Heusen Earnings In Retrospe...

Two weeks ago on December 3rd, 2014 Phillips-Van Heusen (NYSE:PVH) reported earnings an ...